- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06603571
En undersøgelse til undersøgelse af vægtkontrol med LY3841136 og Tirzepatide (LY3298176), alene eller i kombination, hos voksne deltagere med fedme eller overvægt med type 2-diabetes
En fase 2, parallelgruppe, dobbeltblind, placebokontrolleret undersøgelse til undersøgelse af vægtkontrol med LY3841136 og tirzepatid, alene eller i kombination, hos voksne deltagere med fedme eller overvægt med type 2-diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Buenos Aires, Argentina, C1425AGC
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
-
Buenos Aires, Argentina, C1056ABI
- Centro de Investigaciones Metabólicas (CINME)
-
Buenos Aires, Argentina, C1120AAC
- Centro Médico Viamonte
-
Buenos Aires, Argentina, C1405BUB
- Consultorio de Investigación Clínica EMO SRL
-
-
-
-
Arizona
-
Chandler, Arizona, Forenede Stater, 85225
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
-
Phoenix, Arizona, Forenede Stater, 85032
- HOPE Research Institute
-
Scottsdale, Arizona, Forenede Stater, 85260
- Headlands Research - Scottsdale
-
Tucson, Arizona, Forenede Stater, 85712
- The Institute for Liver Health II dba Arizona Liver Health-Tucson
-
-
California
-
Greenbrae, California, Forenede Stater, 94904
- NorCal Medical Research, Inc
-
Huntington Park, California, Forenede Stater, 90255
- Velocity Clinical Research, Huntington Park
-
Rolling Hills Estates, California, Forenede Stater, 90274
- Peninsula Research Associates
-
Walnut Creek, California, Forenede Stater, 94598
- Diablo Clinical Research, Inc.
-
-
Connecticut
-
Stamford, Connecticut, Forenede Stater, 06905
- Stamford Therapeutics Consortium
-
-
Florida
-
Fleming Island, Florida, Forenede Stater, 32003
- Northeast Research Institute (NERI)
-
Hialeah, Florida, Forenede Stater, 33012
- Indago Research & Health Center, Inc
-
Miami, Florida, Forenede Stater, 33165
- New Horizon Research Center
-
New Port Richey, Florida, Forenede Stater, 34652
- Suncoast Clinical Research, Inc.
-
Orlando, Florida, Forenede Stater, 32803
- Charter Research - Winter Park
-
The Villages, Florida, Forenede Stater, 32162
- Charter Research - Lady Lake
-
-
Idaho
-
Ammon, Idaho, Forenede Stater, 83406
- Medical Research Partners
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60640
- Great Lakes Clinical Trials - Andersonville
-
Chicago, Illinois, Forenede Stater, 60640
- Great Lakes Clinical Trials - Ravenswood
-
Skokie, Illinois, Forenede Stater, 60077
- NorthShore University Health System
-
-
Iowa
-
West Des Moines, Iowa, Forenede Stater, 50266
- Iowa Diabetes and Endocrinology Research Center
-
-
Kansas
-
Topeka, Kansas, Forenede Stater, 66606
- Cotton O'Neil Diabetes & Endocrinology
-
-
Massachusetts
-
Needham, Massachusetts, Forenede Stater, 02492
- Knownwell
-
New Bedford, Massachusetts, Forenede Stater, 02740
- Lucida Clinical Trials
-
-
Michigan
-
Southfield, Michigan, Forenede Stater, 48034
- Headlands Research - Detroit
-
Troy, Michigan, Forenede Stater, 48098
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
-
-
Missouri
-
City of Saint Peters, Missouri, Forenede Stater, 63303
- StudyMetrix Research
-
Springfield, Missouri, Forenede Stater, 65807
- Clinvest Headlands Llc
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89128
- Las Vegas Medical Research
-
-
New York
-
Amherst, New York, Forenede Stater, 14226
- Dent Neurologic Institute
-
East Syracuse, New York, Forenede Stater, 13057
- Velocity Clinical Research, Syracuse
-
Port Jefferson Station, New York, Forenede Stater, 11776
- North Suffolk Neurology
-
Rochester, New York, Forenede Stater, 14609
- Rochester Clinical Research, LLC
-
-
North Carolina
-
Greensboro, North Carolina, Forenede Stater, 27405
- Medication Management
-
Monroe, North Carolina, Forenede Stater, 28112
- Monroe Biomedical Research
-
Morehead City, North Carolina, Forenede Stater, 28557
- Lucas Research, Inc
-
New Bern, North Carolina, Forenede Stater, 28562
- Lucas Research, Inc.
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45212
- CTI Clinical Research Center
-
-
South Carolina
-
Greenville, South Carolina, Forenede Stater, 29607
- Tribe Clinical Research, LLC
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37211
- Quality Medical Research
-
-
Texas
-
Austin, Texas, Forenede Stater, 78745
- IMA Clinical Research Austin
-
Dallas, Texas, Forenede Stater, 75230
- Velocity Clinical Research, Dallas
-
Dallas, Texas, Forenede Stater, 75251
- FutureSearch Trials of Dallas
-
Houston, Texas, Forenede Stater, 77079
- PlanIt Research, PLLC
-
San Antonio, Texas, Forenede Stater, 78240
- Endeavor Clinical Trials
-
San Antonio, Texas, Forenede Stater, 78229
- Tekton Research - Fredericksburg Road
-
Weslaco, Texas, Forenede Stater, 78596
- Texas Valley Clinical Research
-
-
Virginia
-
Danville, Virginia, Forenede Stater, 24541
- Spectrum Medical, Inc.
-
-
Washington
-
Wenatchee, Washington, Forenede Stater, 98801
- Central Washington Health Services Association d/b/a Confluence Health
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
W8M-MC-LAA2
- Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²)
- Have Type 2 Diabetes
- Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening
W8M-MC-CWMM:
- Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)
Exclusion Criteria:
W8M-MC-LAA2
-
Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
-
Have an on-going or history of bradyarrhythmia and/or sinus bradycardia
-
Have an elevated resting pulse rate (mean >100 beats per minute (bpm)) or reduced resting pulse rate (mean <60 bpm) at screening
-
Have any of the following cardiovascular conditions within 6 months prior to screening:
- acute myocardial infarction
- cerebrovascular accident (stroke)
- unstable angina, or
- hospitalization due to congestive heart failure
-
Have renal impairment measured as estimated glomerular filtration rate (eGFR) <45 milliliters per minute (mL/min)/1.73 m2
-
Have a history of acute or chronic pancreatitis
-
Have fasting triglycerides >500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening
-
All concomitant medications should be at a stable dose for at least 3 months prior to screening
W8M-MC-CWMM
- Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.
- Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
- Have poorly controlled hypertension.
- Have a history of symptomatic gallbladder disease within the past 2 years
- Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
- Have a lifetime history of suicide attempts.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: LY3841136 Dose 1
Participants will receive LY3841136 subcutaneously (SC) |
Administered SC |
|
Eksperimentel: LY3841136 Dose 2
Participants will receive LY3841136 SC |
Administered SC |
|
Eksperimentel: LY3841136 Dose 3
Participants will receive LY3841136 SC |
Administered SC |
|
Eksperimentel: LY3841136 Dose 1 + Tirzepatide Dose 1
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
Eksperimentel: LY3841136 Dose 2 + Tirzepatide Dose 1
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
Eksperimentel: LY3841136 Dose 2 + Tirzepatide Dose 2
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
Eksperimentel: LY3841136 Dose 3 + Tirzepatide Dose 3
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
Aktiv komparator: Tirzepatide Dose 3
Participants will receive Tirzepatide SC |
Administered SC |
|
Eksperimentel: LY3841136 Dose 2 + Tirzepatide Dose 3
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
Placebo komparator: Placebo
Participants will receive placebo administered SC. |
Administered SC |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Procent ændring fra baseline i kropsvægt
Tidsramme: Baseline, uge 48
|
Baseline, uge 48
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Procentdel af deltagere, der opnår ≥5 % kropsvægtreduktion
Tidsramme: Uge 48
|
Uge 48
|
|
Procentdel af deltagere, der opnår ≥10 % kropsvægtreduktion
Tidsramme: Uge 48
|
Uge 48
|
|
Ændring fra baseline i kropsvægt
Tidsramme: Baseline, uge 48
|
Baseline, uge 48
|
|
Ændring fra baseline i hæmoglobin A1c (HbA1c)
Tidsramme: Baseline, uge 48
|
Baseline, uge 48
|
|
Farmakokinetik (PK): Area Under the Curve (AUC) af LY3841136
Tidsramme: Baseline, uge 48
|
Baseline, uge 48
|
|
PK: Maksimal koncentration (Cmax) af LY3841136
Tidsramme: Baseline, uge 48
|
Baseline, uge 48
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Ernæringsforstyrrelser
- Metaboliske sygdomme
- Overernæring
- Kropsvægt
- Glukosemetabolismeforstyrrelser
- Diabetes mellitus
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Tegn og symptomer
- Overvægtig
- Fedme
- Diabetes mellitus, type 2
- Aminosyrer, peptider og proteiner
- Proteiner
- Glucagon-lignende peptid-1-receptor
- Glucagon-lignende peptidreceptorer
- Receptorer, G-protein-koblet
- Receptorer, celleoverflade
- Membranproteiner
- Receptorer, gastrointestinal hormon
- Receptorer, peptid
- Tirzepatid
Andre undersøgelses-id-numre
- 18809
- W8M-MC-LAA2 (Anden identifikator: Eli Lilly and Company)
- W8M-MC-CWMM Master Protocol (Anden identifikator: Eli Lilly and Company)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD-delingstidsramme
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD-delingsadgangskriterier
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .